Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Rises By 384.2%

Pulmatrix, Inc. (NASDAQ:PULM) saw a significant increase in short interest in August. As of August 31st, there was short interest totaling 20,198 shares, an increase of 384.2% from the August 15th total of 4,171 shares. Currently, 0.6% of the company’s stock are short sold. Based on an average trading volume of 12,801 shares, the short-interest ratio is presently 1.6 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Pulmatrix Price Performance

NASDAQ:PULM traded down $0.02 during trading hours on Friday, hitting $1.44. 7,270 shares of the company were exchanged, compared to its average volume of 29,072. The company’s 50 day moving average price is $1.60 and its 200-day moving average price is $1.61. The stock has a market capitalization of $5.26 million, a price-to-earnings ratio of -1.31 and a beta of 1.90. Pulmatrix has a 52-week low of $1.16 and a 52-week high of $5.50.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.00) by $1.71.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PULM. Dimensional Fund Advisors LP acquired a new stake in Pulmatrix during the 3rd quarter worth about $52,000. DRW Securities LLC acquired a new position in shares of Pulmatrix in the 4th quarter valued at about $46,000. Finally, BlackRock Inc. acquired a new position in shares of Pulmatrix in the 2nd quarter valued at about $93,000. 11.84% of the stock is currently owned by institutional investors and hedge funds.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).